Oncology Drugs Export of France: The Trade Analysis of 2024

Oncology Medications are the drugs used for the prevention and proper treatment of cancer in healthcare facilities. Oncology drugs encompass a wide range of essential medical treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. The global trade of this pharmaceutical is continued due to the prevalence of cancer in a global manner and the ability of only a few countries to produce it in advanced production. France Import Data says, the country in Western Europe, bordered by Belgium and Germany to the north and east, has gradually emerged as a substantial contributor to the worldwide export market of oncology drugs due to its large pharmaceutical manufacturing base and the robust contract manufacturing sector.

The country, with its integration of API suppliers and world-class scientific research ecosystem, has been maintaining a solid rank among the global competitors. The high participation of the country in oncology clinical trials and the public-private research collaborations has resulted in an export valuation of oncology drugs worth 10 billion US dollars in 2024. The export promotion support for agencies and the trade agreements within the EU have been facilitating the overall revenue rates. Subscribe to Import Globals, the leading oncology drugs import export trade provider, to stay updated with the latest information regarding the France Oncology Exports with France Trade Data.

GOVERNMENT INITIATIVES SUPPORTING THE ONCOLOGY DRUGS EXPORT OF FRANCE IN 2024

The France 2030 investment plan has accelerated the research and industrial development across the oncology drug value chains. It has even made the country a more attractive base for biotech research and development. The innovations in biotherapies and bioproduction call have helped French biotech firms build export-ready manufacturing platforms.

The demo funding via France 2030 has supported cutting-edge cancer immunotherapy candidates and has even strengthened the pipeline of high-value oncology drugs. The export plan has enhanced the export readiness of smaller oncology drug developers.

THE LEADING VARIANTS OF ONCOLOGY DRUGS EXPORTED BY FRANCE IN 2024

France, due to the government prioritization of the healthcare industry and the strategic location within Europe for distribution, has actively reported a divergent variant of its domestic pharmaceutical production in the global trade output. According to the France Export Data, the topmost variants of oncology drugs exported from the nation in 2024 are,

  • Monoclonal Antibodies — The annual valuation of Monoclonal Antibodies exported from France in 2024–3.21 billion US dollars
  • Immune Checkpoint Inhibitors- The annual valuation of Immune Checkpoint Inhibitors exported from France in 2024–2.24 billion US dollars
  • Antineoplastic ChemotherapyAgents- The annual valuation of Antineoplastic Chemotherapy Agentsexported from France in 2024–1.76 billion US dollars
  • Targeted Small-Molecule Therapies- The annual valuation of Targeted Small-Molecule Therapies exported from France in 2024–1.28 billion US dollars
  • Hormonal Therapy Drugs- The annual valuation of Hormonal Therapy Drugs exported from France in 2024–1 billion US dollars
  • Antibody–Drug Conjugates- The annual valuation of Antibody–Drug Conjugates exported from France in 2024–919 million US dollars
  • Cancer Vaccines- The annual valuation of Cancer Vaccines exported from France in 2024–765 million US dollars
  • Radiopharmaceuticals- The annual valuation of Radiopharmaceuticals exported from France in 2024–654 million US dollars
  • Biosimilar Oncology Drugs- The annual valuation of Biosimilar Oncology Drugs exported from France in 2024–565 million US dollars
  • Cell and Gene Therapy Products- The annual valuation of Cell and Gene Therapy Products exported from France in 2024–478 million US dollars

TOP TRADE PARTNERS OF FRANCE IN 2024

The world-class ecosystem based on the latest research technologies and the strong biotech memorandum, followed by the healthcare facilities, has maintained the integrity of the nation with the topmost demanding regions. As per the France Customs Data, the topmost trade partners shaping the oncology drugs export of the nation in 2024 are,

  • Germany — The total valuation of oncology drugs exported from France to Germany in 2024–3.21 billion US dollars

Top 5 variants of oncology drugs exported

  • T-cell engagers (BiTEs)
  • Cytokine therapy agents
  • Oncolytic viruses
  • CAR-T cell therapies
  • Tumor-infiltrating lymphocytes
  • United States — The total valuation of oncology drugs exported from France to United States in 2024–2.42 billion US dollars

Top 5 variants of oncology drugs exported

  • HER2-targeting ADCs
  • CD30-targeting ADCs
  • CD33-targeting ADCs
  • CD22-targeting ADCs
  • Nectin-4-targeting ADCs
  • Italy — The total valuation of oncology drugs exported from France to Italy in 2024–1.89 billion US dollars

Top 5 variants of oncology drugs exported

  • SLAMF7-targeting antibodies
  • Anti-IL-6 receptor antibodies
  • Anti-CCR4 antibodies
  • Anti-CD52 antibodies
  • Anti-TNF-α antibodies
  • Spain — The total valuation of oncology drugs exported from France to Spain in 2024–1.65 billion US dollars

Top 5 variants of oncology drugs exported

  • HER2-targeting antibodies
  • CD20-targeting antibodies
  • EGFR-targeting antibodies
  • VEGF-targeting antibodies
  • CD38-targeting antibodies
  • Belgium — The total valuation of oncology drugs exported from France to Belgium in 2024–1.42 billion US dollars

Top 5 variants of oncology drugs exported

  • HER2 inhibitors
  • RET inhibitors
  • KIT inhibitors
  • FGFR inhibitors
  • JAK inhibitors
  • United Kingdom — The total valuation of oncology drugs exported from France to United Kingdom in 2024–1.28 billion US dollars

Top 5 variants of oncology drugs exported

  • Tyrosine kinase inhibitors
  • EGFR inhibitors
  • VEGF inhibitors
  • ALK inhibitors
  • BRAF inhibitors
  • Netherlands — The total valuation of oncology drugs exported from France to the Netherlands in 2024–1.08 billion US dollars

Top 5 variants of oncology drugs exported

  • DNA-intercalating agents
  • Anticancer enzyme inhibitors
  • Nitroimidazoles
  • Uracil analogs
  • Etoposide-class agents
  • China — The total valuation of oncology drugs exported from France to China in 2024–919 million US dollars

Top 5 variants of oncology drugs exported

  • Epothilones
  • Camptothecins
  • Folate antagonists
  • Purine analogs
  • Pyrimidine analogs
  • Switzerland — The total valuation of oncology drugs exported from France to Switzerland in 2024–765 million US dollars

Top 5 variants of oncology drugs exported

  • Mitotic inhibitors
  • Platinum-based agents
  • Anthracyclines
  • Vinca alkaloids
  • Taxanes
  • Poland — The total valuation of oncology drugs exported from France to Poland in 2024–642 million US dollars

Top 5 variants of oncology drugs exported

  • Alkylating agents
  • Antimetabolites
  • Anti-tumor antibiotics
  • Topoisomerase I inhibitors
  • Topoisomerase II inhibitors

Comments

Popular posts from this blog

Overview of the Optical Equipment Import of Vietnam in 2023

An in-depth Analysis of Gold, Nicaragua's Top Export

Seafood Export of Uganda in 2023